Evidence map›Paper›PMID 35952703›Full record

ReviewThe Lancet. Infectious diseases2023

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.

Natalie I Mazur, Jonne Terstappen, Ranju Baral, Azucena Bardají, Philippe Beutels, Ursula J Buchholz, Cheryl Cohen, James E Crowe, Clare L Cutland, Linda Eckert and 31 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 11 pooled it
63.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 11 syntheses or guidelines pooled it, 420 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Programmed cell death in human respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  19. Article
  20. Review

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 20 institutions in 12 countries.

Natalie I MazurDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
Jonne TerstappenDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
Ranju BaralPATH, Center for Vaccine Innovation & Access, Seattle, WA, USA.
Azucena BardajíISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain; Centro de Investigaçao em Saúde de Manhiça, Maputo, Mozambique; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.
Philippe BeutelsCentre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; School of Public Health, The University of New South Wales, Sydney, NSW, Australia.
Ursula J BuchholzRNA Viruses Section, Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, MA, USA.
Cheryl CohenUniversity of the Witwatersrand, Centre for Respiratory Disease and Meningitis at the National Institute for Communicable Diseases, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
James E CroweVanderbilt Vaccine Center, Pediatrics & Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Clare L CutlandAfrican Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Linda EckertObstetrics & Gynecology, Global Health, University of Washington, Seattle, WA, USA.
Daniel FeikinDepartment of Immunisations, Vaccines & Biologicals, World Health Organization, Geneva, Switzerland.
Tiffany FitzpatrickYale School of Public Health Department of Epidemiology of Microbial Diseases, Yale University, New Haven, CT, USA.
Youyi FongVaccine & Infectious Disease Division, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Department of Biostatistics, University of Washington, Seattle, WA, USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MA, USA.
Terho HeikkinenDepartment of Pediatrics, University of Turku and Turku University Hospital, Turku, Finland.
Deborah HigginsPATH, Center for Vaccine Innovation & Access, Seattle, WA, USA.
Siddhivinayak HirveGlobal Influenza Programme, World Health Organization, Geneva, Switzerland.
Keith P KlugmanPneumonia Program, Bill & Melinda Gates Foundation, Seattle, WA, USA.
Leyla Kragten-TabatabaieReSViNET Foundation, Julius Clinical, Zeist, Netherlands.
Philippe LemeyClinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Romina LibsterFundacion INFANT, Buenos Aires, Argentina.
Yvette LöwensteynDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
Asuncion MejiasNationwide Children's Hospital Columbus, Columbus, OH, USA.
Flor M MunozDepartment of Pediatrics, Division of Infectious Disease, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
Patrick K MunywokiKenyan Medical Research Institute-Wellcome Trust Research Program, Kilifi, Kenya.
Lawrence MwananyandaDepartment of Global Health, Boston University, Lusaka, Zambia.
Harish NairCentre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
Marta C NunesSouth African Medical Research Council, Wits Vaccines & Infectious Diseases Analytics Research Unit and Department of Science and Technology and National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Octavio RamiloNationwide Children's Hospital Columbus, Columbus, OH, USA.
Peter RichmondSchool of Medicine, Division of Paediatrics, University of Western Australia, Perth, WA, Australia.
Tracy J RuckwardtVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MA, USA.
Charles SandeKenyan Medical Research Institute-Wellcome Trust Research Program, Kilifi, Kenya; Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK.
Padmini SrikantiahRespiratory Syncytial Virus Program and Global Health, Bill & Melinda Gates Foundation, Seattle, WA, USA.
Naveen ThackerDeep Children Hospital & Research Centre, Gandhidham, India.
Kody A WaldsteinDepartment of Microbiology and Immunology, University of Iowa, Iowa, IA, USA; Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa, IA, USA.
Dan WeinbergerYale School of Public Health Department of Epidemiology of Microbial Diseases, Yale University, New Haven, CT, USA.
Joanne WildenbeestDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
Dexter WisemanNational Heart & Lung Institute, Imperial College, London, UK.
Heather J ZarDepartment of Pediatrics & Child Health, Red Cross Children's Hospital and SA-MRC unit of Child & Adolescent Health, University of Cape Town, Cape Town, South Africa.
Maria ZambonReference Microbiology, Public Health England, Faculty of Medicine, Imperial College, London, UK.
Louis BontDepartment of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands; ReSViNET Foundation, Julius Clinical, Zeist, Netherlands. Electronic address: l.bont@umcutrecht.nl.
University Medical Center Utrecht · NLBill & Melinda Gates Foundation · USImperial College London · GBKenya Medical Research Institute · KENational Institutes of Health · USNationwide Children's Hospital · USProgram for Appropriate Technology in Health · USUniversity of the Witwatersrand · ZAWilhelmina Children's Hospital · NLWorld Health Organization · CHYale University · USBaylor College of Medicine · USFred Hutch Cancer Center · USInfant Foundation · ARKU Leuven · BENational Institute of Allergy and Infectious Diseases · USNational Research Foundation · ZAUniversitat de Barcelona · ESUniversity of Antwerp · BEUniversity of Cape Town · ZA

Funding

Vaccine Research and Development for Endemic, Emerging, and Resurgent VirusesZIAAI005128 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2016 to 2025
$50.8M
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related VirusesZIAAI000326 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BUCHHOLZ, URSULA · 2009 to 2025
$33.1M
Intramural NIH HHS ZIA AI000326World Health Organization 001
6 · The paper itself

Abstract

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. Nine candidates are in phase 3 clinical trials. Understanding the epitopes targeted by highly neutralising antibodies has resulted in a shift from empirical to rational and structure-based vaccine and monoclonal antibody design. An extended half-life monoclonal antibody for all infants is likely to be within 1 year of regulatory approval (from August, 2022) for high-income countries. Live-attenuated vaccines are in development for older infants (aged >6 months). Subunit vaccines are in late-stage trials for pregnant women to protect infants, whereas vector, subunit, and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of a respiratory syncytial virus vaccine globally. This review gives an overview of respiratory syncytial virus vaccines and monoclonal antibodies in clinical development highlighting different target populations, antigens, and trial results.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAntibodies, MonoclonalAntibodies, ViralFemaleHumansImmunizationInfantPregnancyAntibodies, MonoclonalAntibodies, ViralRespiratory Syncytial Virus Vaccines

Identifiers

PMID35952703
PMCPMC9896921
OpenAlexW4297452555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.